PL2952209T3 - Jednorodne formulacje zawierające wielonienasycone kwasy tłuszczowe omega-3 (n-3 PUFA) i resweratrol do podawania doustnego - Google Patents

Jednorodne formulacje zawierające wielonienasycone kwasy tłuszczowe omega-3 (n-3 PUFA) i resweratrol do podawania doustnego

Info

Publication number
PL2952209T3
PL2952209T3 PL14001941T PL14001941T PL2952209T3 PL 2952209 T3 PL2952209 T3 PL 2952209T3 PL 14001941 T PL14001941 T PL 14001941T PL 14001941 T PL14001941 T PL 14001941T PL 2952209 T3 PL2952209 T3 PL 2952209T3
Authority
PL
Poland
Prior art keywords
pufa
resveratrol
fatty acids
oral administration
polyunsaturated fatty
Prior art date
Application number
PL14001941T
Other languages
English (en)
Polish (pl)
Inventor
Mosè Santaniello
Giuseppe Giannini
Original Assignee
Alfasigma S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma S P A filed Critical Alfasigma S P A
Publication of PL2952209T3 publication Critical patent/PL2952209T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
PL14001941T 2014-06-04 2014-06-04 Jednorodne formulacje zawierające wielonienasycone kwasy tłuszczowe omega-3 (n-3 PUFA) i resweratrol do podawania doustnego PL2952209T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14001941.5A EP2952209B1 (en) 2014-06-04 2014-06-04 Homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration

Publications (1)

Publication Number Publication Date
PL2952209T3 true PL2952209T3 (pl) 2018-07-31

Family

ID=50884651

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14001941T PL2952209T3 (pl) 2014-06-04 2014-06-04 Jednorodne formulacje zawierające wielonienasycone kwasy tłuszczowe omega-3 (n-3 PUFA) i resweratrol do podawania doustnego

Country Status (13)

Country Link
US (1) US10300035B2 (OSRAM)
EP (1) EP2952209B1 (OSRAM)
JP (1) JP6552526B2 (OSRAM)
CN (1) CN106456783B (OSRAM)
AU (1) AU2015271277A1 (OSRAM)
CA (1) CA2943000A1 (OSRAM)
EA (1) EA032717B1 (OSRAM)
ES (1) ES2666836T3 (OSRAM)
MX (1) MX361765B (OSRAM)
PL (1) PL2952209T3 (OSRAM)
PT (1) PT2952209T (OSRAM)
UA (1) UA118289C2 (OSRAM)
WO (1) WO2015185238A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120053661A (zh) * 2022-05-06 2025-05-30 太阳雨林(北京)生物医药有限公司 预防、阻止或治疗微生物感染的亲水性脂肪酸类复合物及其制备和应用
JP2025516384A (ja) * 2022-05-06 2025-05-27 太陽雨林（北京）生物医薬有限公司 細胞膜の膜貫通輸送及び流動性を調節する炭素鎖物質、その調製及び使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
ITRM20020562A1 (it) 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
GB2438566A (en) * 2005-03-11 2007-11-28 Recon Oil Ind Private Ltd A synergistically heat stable oil media having eicosa pentaenoic acid (EPA) and docosa hexaenoic acid (DHA)
DE202008003509U1 (de) * 2008-03-12 2009-10-15 Langhoff, Gertrud Pharmazeutische Zusammensetzung zur Prophylaxe und Behandlung der Arteriosklerose, sowie zur Schmerzbekämpfung und zur Entzündungshemmung
KR101100078B1 (ko) * 2008-03-27 2011-12-29 홉킨스바이오연구센터(주) 관절염 치료를 위한 약제학적 조성물
KR20120104270A (ko) 2009-12-23 2012-09-20 데피안떼 파마슈띠까 에스.에이. 심혈관계 질환 치료에 유용한 복합 조성물
US20110244031A1 (en) 2010-03-31 2011-10-06 Lifecycle Pharma A/S Porous tablets as carriers for liquid formulations
IT1400695B1 (it) 2010-06-21 2013-06-28 Labomar S R L Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle.
US8741373B2 (en) * 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
CN102228089B (zh) * 2011-06-22 2013-02-20 刘升胜 一种天然复合食用植物健脑营养饮料
KR101418980B1 (ko) * 2012-04-24 2014-07-11 (주)바이오제닉스 난용성 물질을 가용화 하는 다중 라멜라 액정의 제조방법
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
WO2014095628A1 (en) * 2012-12-17 2014-06-26 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oral formulation containing a statin in omega-3 polyunsaturated fatty acids (n-3 pufa)

Also Published As

Publication number Publication date
EP2952209B1 (en) 2018-03-28
JP6552526B2 (ja) 2019-07-31
CA2943000A1 (en) 2015-12-10
ES2666836T3 (es) 2018-05-08
CN106456783B (zh) 2020-06-12
PT2952209T (pt) 2018-05-09
JP2017516820A (ja) 2017-06-22
US20170119720A1 (en) 2017-05-04
EP2952209A1 (en) 2015-12-09
US10300035B2 (en) 2019-05-28
WO2015185238A1 (en) 2015-12-10
MX2016013190A (es) 2017-01-09
EA032717B1 (ru) 2019-07-31
EA201692398A1 (ru) 2017-04-28
CN106456783A (zh) 2017-02-22
AU2015271277A1 (en) 2016-11-10
UA118289C2 (uk) 2018-12-26
MX361765B (es) 2018-12-17

Similar Documents

Publication Publication Date Title
HUE048494T2 (hu) Eljárás többszörösen telítetlen omega-3 zsírsavakat tartalmazó készítmény stabilitásának növelésére
EP3763364C0 (en) SELF-EMULSIFYING OMEGA-3 FATTY ACID COMPOSITION
SG11201705938TA (en) SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
EP3248599A4 (en) Omega-3 fatty acid self-emulsifying composition
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
PL3294850T3 (pl) Wielonienasycone kwasy tłuszczowe o bardzo długich łańcuchach z naturalnych olejów
DK3310333T3 (da) Oralt dispergibel doseringsenhed indeholdende en estetrolkomponent
ZA201704821B (en) Process for increasing the stability of a composition comprising polyunsaturated omega-6 fatty acids
ZA201700275B (en) Cleaning compositions containing high fatty acids
IL283357A (en) Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters
EP3069615A4 (en) Fat containing polyunsaturated fatty acid
SG11201803022TA (en) Compositions comprising fatty acids and their use
IL271961A (en) The compositions containing thymoquinone and omega-3 fatty acids
IL249757A0 (en) Preparations containing mbx-8025, its salts and niacin fibrate or omega-3 fatty acid, kits containing them and their uses
MA40417A (fr) Mélange d'acides gras et de palmitoyl éthanolamide pour utilisation dans le traitement de pathologies inflammatoires et allergiques
ZA201705620B (en) Millicapsule formulations comprising polyunsaturated free fatty acids
GB201611497D0 (en) Compositions for use in enriching animal meat with omega-3 polyunsaturated fatty acids
PL3346980T3 (pl) Lipofilowe kompozycje kosmetyczne zawierające estry kwasu pelargonowego
PL3784044T3 (pl) Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha
PL2952209T3 (pl) Jednorodne formulacje zawierające wielonienasycone kwasy tłuszczowe omega-3 (n-3 PUFA) i resweratrol do podawania doustnego
PL3560342T3 (pl) Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha
PL3809860T3 (pl) Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha
PL3809858T3 (pl) Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha
PL2952180T3 (pl) STAŁE FORMULACJE ZAWIERAJĄCE RESWERATROL I WIELONIENASYCONE KWASY TŁUSZCZOWE OMEGA-3 (n-3 PUFA)
GB201611503D0 (en) Compositions for use in enriching animal meat with omega-3 polyunsaturated fatty acids